Expression Quantitative Trait Locus Analysis in Systemic Sclerosis Identifies New Candidate Genes Associated With Multiple Aspects of Disease Pathology
Metadatos
Mostrar el registro completo del ítemAutor
Kerick, Martin; González-Serna, David; Carnero Montoro, Elena; Teruel, Maria; Acosta Herrera, Marialbert; Makowska, Zuzanna; Buttgereit, Anne; Babaei, Sepideh; Barturen, Guillermo; López Isac, Elena; PRECISESADS Clinical Consortium; Lesche, Ralf; Beretta, Lorenzo; Alarcón Riquelme, Marta Eugenia; Martin, JavierEditorial
Wiley
Fecha
2021Referencia bibliográfica
Kerick M, González-Serna D, Carnero-Montoro E, Teruel M, Acosta-Herrera M, Makowska Z, Buttgereit A, Babaei S, Barturen G, López-Isac E; PRECISESADS Clinical Consortium; Lesche R, Beretta L, Alarcon-Riquelme ME, Martin J. Expression Quantitative Trait Locus Analysis in Systemic Sclerosis Identifies New Candidate Genes Associated With Multiple Aspects of Disease Pathology. Arthritis Rheumatol. 2021 Jul;73(7):1288-1300. doi: 10.1002/art.41657. Epub 2021 May 28. PMID: 33455083.
Patrocinador
Supported by the Innovative Medicines Initiative Joint UndertakingPRECISE Systemic Autoimmune Diseases Project (grant 115565), the Span-ish Ministry of Science and Innovation (grants RTI2018101332-B- 100and SAF2015-66761-P), and the Red de Investigación en Inflamación yEnfermedades Reumáticas through the Instituto de Salud Carlos III (grantRD16/0012/0013). The Genotype-Tissue Expression Project was supported bythe National Cancer Institute, National Human Genome Research Institute,National Heart, Lung, and Blood Institute, National Institute on Drug Abuse,National Institute of Mental Health, and National Institute of NeurologicalDisorders and Stroke, NIH and by the NIH Common Fund. Mr. González-Serna’s work was supported by the Spanish Ministry of Economy andCompetitiveness FPI Program (grant SAF2015-66761-P). Dr. Acosta-Herrera’swork was supported by the Spanish Ministry of Science and Innovation Juande la Cierva Incorporación Program (grant IJC2018-035131-I)Resumen
Objective: To identify the genetic variants that affect gene expression (expression quantitative trait loci [eQTLs]) in systemic sclerosis (SSc) and to investigate their role in the pathogenesis of the disease.
Methods: We performed an eQTL analysis using whole-blood sequencing data from 333 SSc patients and 524 controls and integrated them with SSc genome-wide association study (GWAS) data. We integrated our findings from expression modeling, differential expression analysis, and transcription factor binding site enrichment with key clinical features of SSc.
Results: We detected 49,123 validated cis-eQTLs from 4,539 SSc-associated single-nucleotide polymorphisms (SNPs) (PGWAS < 10-5 ). A total of 1,436 genes were within 1 Mb of the 4,539 SSc-associated SNPs. Of those 1,436 genes, 565 were detected as having ≥1 eQTL with an SSc-associated SNP. We developed a strategy to prioritize disease-associated genes based on their expression variance explained by SSc eQTLs (r2 > 0.05). As a result, 233 candidates were identified, 134 (58%) of them associated with hallmarks of SSc and 105 (45%) of them differentially expressed in the blood cells, skin, or lung tissue of SSc patients. Transcription factor binding site analysis revealed enriched motifs of 24 transcription factors (5%) among SSc eQTLs, 5 of which were found to be differentially regulated in the blood cells (ELF1 and MGA), skin (KLF4 and ID4), and lungs (TBX4) of SSc patients. Ten candidate genes (4%) can be targeted by approved medications for immune-mediated diseases, of which only 3 have been tested in clinical trials in patients with SSc.
Conclusion: The findings of the present study indicate a new layer to the molecular complexity of SSc, contributing to a better understanding of the pathogenesis of the disease.